Agenus is a clinical-stage immuno-oncology company which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. The Company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies, SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies, and phage display technologies. It is also developing checkpoint modulating antibody candidates. In addition, the Company develops cancer and tumor vaccine programs and a saponin-based vaccine adjuvant for the treatment of malaria and shingles.

Employee Rating

3.1More
TypePublic
HQLexington, US
Founded1994
Size (employees)255 (est)
Websiteagenusbio.com
Agenus was founded in 1994 and is headquartered in Lexington, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Agenus

Garo Armen

Garo Armen

PhD, Chairman and CEO
Jennifer Buell

Jennifer Buell

PhD, Chief Operating Officer
Ozer Baysal

Ozer Baysal

Chief Commercial Officer and Head of Human Resources
Alex Duncan

Alex Duncan

PhD, Chief Technology Officer and Head of Research
Christian Cortis

Christian Cortis

PhD, Chief Strategy Officer & Head of Finance
Show more

Agenus Office Locations

Agenus has offices in Lexington, Berkeley, New York and Cambridge
Lexington, US (HQ)
3 Forbes Road
Berkeley, US
793 Heinz Ave
New York, US
149 Fifth Ave. Suite 500
Cambridge, GB
315 Science Park Milton Road
Show all (4)
Report incorrect company information

Agenus Financials and Metrics

Agenus Revenue

Agenus's revenue was reported to be $42.88 m in FY, 2017
USD

Revenue (Q3, 2018)

12.8m

Net income (Q3, 2018)

(33.7m)

EBIT (Q3, 2018)

(26.1m)

Market capitalization (14-Dec-2018)

290.4m

Closing stock price (14-Dec-2018)

2.4

Cash (30-Sep-2018)

46.2m

EV

257.4m
Agenus's current market capitalization is $290.4 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

3.0m7.0m24.8m22.6m42.9m

Revenue growth, %

129%256%(9%)

Cost of goods sold

536.1k

Gross profit

2.5m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

736.0k720.9k3.1m1.6m4.0m6.4m6.8m6.0m6.6m4.4m27.0m4.2m3.4m1.6m15.9m12.8m

General and administrative expense

3.6m5.2m5.8m4.9m5.5m8.0m6.4m9.2m7.1m8.1m7.8m8.1m8.1m8.9m9.5m9.2m

R&D expense

3.9m4.5m5.2m5.3m9.2m24.8m18.5m5.8m6.6m4.4m27.0m4.2m3.4m29.4m29.3m29.9m

Operating expense total

7.5m9.6m11.1m10.2m14.7m32.8m24.9m15.0m13.7m12.6m34.7m12.3m11.4m38.4m77.1m39.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

27.4m25.7m136.7m71.4m60.2m

Accounts Receivable

1.2k9.8m11.4m1.1m

Inventories

95.7k88.2k88.2k79.5k

Current Assets

28.2m42.7m184.1m91.3m73.6m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

30.2m73.5m48.3m38.4m79.3m124.7m184.1m78.3m73.4m75.4m113.9m81.8m65.1m52.3m43.2m46.2m

Accounts Receivable

1.1k2.5m4.1m7.3m10.2m9.4m10.3m6.8m3.9m2.2m1.1m10.9m6.1m

Inventories

3.3k95.7k95.7k88.2k88.2k88.2k88.2k88.2k88.2k87.5k87.0k80.2k62.2k55.5k55.5k

Current Assets

30.9m75.3m67.0m55.2m85.2m146.3m208.9m161.6m136.1m109.5m138.0m110.7m84.3m65.2m67.7m67.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(30.1m)(42.5m)(87.9m)(127.0m)(120.7m)

Depreciation and Amortization

586.3k1.6m2.0m4.9m6.0m

Inventories

16.0k(95.7k)7.5k7.5k8.7k

Accounts Payable

189.6k(45.9k)2.7m419.7k1.6m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(24.3m)(357.5k)(8.4m)(16.5m)(18.7m)(59.2m)(72.3m)(31.8m)(60.1m)(100.9m)(17.1m)(48.8m)(85.7m)(54.3m)(79.5m)(113.2m)

Depreciation and Amortization

448.2k266.5k589.4k1.0m445.5k885.5k1.4m1.2m2.5m3.7m1.5m3.1m4.6m1.6m3.1m4.7m

Inventories

12.7k(95.7k)(95.7k)7.5k7.5k7.5k88.2k88.2k88.2k87.5k8.0k17.3k24.0k24.0k

Accounts Payable

(269.4k)184.0k(562.1k)35.2k2.3m797.8k1.3m(2.3m)474.5k(1.3m)(1.1m)(1.2m)1.0m(2.8m)1.7m2.9m
USDY, 2018

EV/EBIT

-9.9 x

EV/CFO

-2.7 x

Debt/Equity

-0.1 x

Debt/Assets

0.1 x

Financial Leverage

-1 x
Show all financial metrics
Report incorrect company information

Agenus Online and Social Media Presence

Embed Graph
Report incorrect company information

Agenus News and Updates

Agenus to Present at the 2018 Jefferies London Healthcare Conference

LEXINGTON, Mass., Nov. 13, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, announced today that Dr. Jennifer Buell, Chief External Affairs Officer at Agenus, will...

Agenus to Present Data on Neoantigen Vaccines and anti-CD137 Antibody at SITC 2018

LEXINGTON, Mass., Nov. 6, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, will present new data on several of its programs – including AutoSynVax™ (ASV™), discovery...

Agenus Reports Third Quarter 2018 Financial Results and Provides Corporate Update

LEXINGTON, Mass., Nov. 6, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, provided a corporate update and reported financial results for the third quarter of...

Agenus to Report Third Quarter 2018 Financial Results on November 6, 2018 and Host Conference Call and Webcast

LEXINGTON, Mass., Oct. 31, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, will release its third quarter 2018 financial results before the market opens on Tuesday,...

Global Checkpoint Inhibitors Markets 2018-2023 with Profiles of Agenus, BeiGene, BIOCAD, Forty Seven, Seattle Genetics, Shanghai Cell Therapy, Tesaro and Xencor

DUBLIN, Oct. 23, 2018 /PRNewswire/ -- The "Checkpoint Inhibitors: Global Markets" report has been added to ResearchAndMarkets.com's offering. This report on checkpoint inhibitors provides a detailed analysis of the market based on approved clinical and preclinical developmental candidates ...

Agenus Presents Clinical Data on Its PD-1 & CTLA-4 at ESMO 2018

LEXINGTON, Mass., Oct. 20, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies2, presented updated clinical data on its lead CTLA-4 and PD-1 programs today at the 2018...
Show more
Report incorrect company information

Agenus Blogs

Agenus Presents Clinical Data on Its PD-1 & CTLA-4 at ESMO 2018

- Patients treated with Agenus' PD-1 & CTLA-4 antibodies show durable clinical benefit1 in early analyses

Agenus To Present Data on Proprietary CTLA-4 & PD-1 Antibodies at ESMO 2018

- AGEN PD-1 antibody (AGEN2034) shows early signs of clinical activity in patients with cervical cancer

Agenus Reports Second Quarter 2018 Financial Results and Provides Corporate Update

- Cash milestones earned from Merck & Incyte

Agenus Company Life and Culture

Report incorrect company information

Agenus Frequently Asked Questions

  • When was Agenus founded?

    Agenus was founded in 1994.

  • Who are Agenus key executives?

    Agenus's key executives are Garo Armen, Jennifer Buell and Ozer Baysal.

  • How many employees does Agenus have?

    Agenus has 255 employees.

  • What is Agenus revenue?

    Latest Agenus annual revenue is $42.9 m.

  • What is Agenus revenue per employee?

    Latest Agenus revenue per employee is $168.1 k.

  • Who are Agenus competitors?

    Competitors of Agenus include Regeneron Pharmaceuticals, ImmunoCellular Therapeutics and Medivir.

  • Where is Agenus headquarters?

    Agenus headquarters is located at 3 Forbes Road , Lexington.

  • Where are Agenus offices?

    Agenus has offices in Lexington, Berkeley, New York and Cambridge.

  • How many offices does Agenus have?

    Agenus has 4 offices.